Drug Type Bispecific antibody |
Synonyms TAA16/13_BsAb, TAA16/13 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anaplastic Large-Cell Lymphoma | Preclinical | China | 22 May 2023 | |
| NK-cell lymphoma | Preclinical | China | 22 May 2023 | |
| Peripheral T-Cell Lymphoma | Preclinical | China | 22 May 2023 |






